AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05258266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: Q.D., oral dosing
Study NCT04813068 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview to identify attitudes to re-irradiation in lung cancer
Study NCT05970510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg
Description: orally once a day
Study NCT05970510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
Description: orally once a day
Study NCT05970510 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: orally once a day
Study NCT05001009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low patient engagement
Description: Patients will be sent information about goals of care conversations, including the PREPARE website.
Study NCT05001009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High patient engagement
Description: Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
Study NCT06525623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation: No Further Resuscitation
Description: Treatment teams are encouraged not to administer any additional fluids
Study NCT06525623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation: Resuscitation with Crystalloid
Description: Treatment teams are encouraged to administer crystalloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
Study NCT06525623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation: Resuscitation with Colloid
Description: Treatment teams are encouraged to administer colloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
Study NCT06525623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Recommendation: Standard of Care IV Albumin
Description: Treatment teams are encouraged to administer 1 g/kg/d IV albumin (maximum 100 g/day) over 2 days
Study NCT06561711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium competitive acid blocker
Study NCT06561711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Potassium competitive acid blocker
Study NCT06561711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT06561711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT06561711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline,Metronidazole
Description: Antibiotics for H. pylori eradication
Study NCT06561711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline,Metronidazole
Description: Antibiotics for H. pylori eradication
Study NCT06245083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrroloquinoline quinone (PQQ)
Description: Oral supplement taken daily
Study NCT06245083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with soybean oil
Description: Oral supplement taken daily
Study NCT06216743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI and CT
Description: Patients will undergo an additional MRI, cineMRI and CineCT cscan.
Study NCT05769478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine
Description: a single dose of amifampridine (20mg) will be orally administered
Study NCT04847297 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative drainage and pancreatoduodenectomy
Description: Preoperative biliary drainage before surgical removal of the tumor
Study NCT06282016 — intervention group
Intervention type: OTHER
Intervention: Case-control study (no intervention)
Description: Observation of risk factors in cases and controls
Study NCT04847297 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreatoduodenectomy
Description: Pancreatic tumor resection without previous preoperative biliary drainage
Study NCT05723497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elderberry juice
Description: Participants will consume elderberry juice 1-week.
Study NCT05723497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: Participants will consume placebo for 1-week.
Study NCT06205407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris
Description: Manufactured at Viatris
Study NCT06205407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Description: Manufactured at Neolpharma.
Study NCT05765890 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT06558825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention to Promote PrEP Uptake
Description: Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting.
Study NCT06558825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Condition
Description: Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
Study NCT05362253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation
Description: 1. Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~2. The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~3. After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~4. Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm \~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~5. Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing.
Study NCT05362253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Autologous Conjunctival Transplantation
Description: 1. Routine disinfection and anaesthesia.~2. To bluntly separate and excise pterygium.~3. Remove pterygium tissue on the corneal surface with a round blade.~4. Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~5. After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~6. The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~7. Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation.
Study NCT06158607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders
Description: Provision of PrEP information through 4 counseling sessions, prevention navigation, and nurse practitioner prescribed PrEP in an addiction treatment setting.
Study NCT06158607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Participants in substance use treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
Study NCT04365660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-F FTC 146
Description: Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
Study NCT04988308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.
Study NCT04769518 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Recovery Room Care (ARRC)
Description: High acuity care
Study NCT04988308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.
Study NCT04769518 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Advanced Recovery Room Care (ARRC)
Description: High acuity care
Study NCT05225610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valsalva Manoeuvre
Description: Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds
Study NCT05225610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
Study NCT05225610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: 5 ml saline will be administered.
Study NCT04988308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be administered subcutaneously.
Study NCT04988308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT04988308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT04988308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT06470217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirilizumab with albumin-bound paclitaxel and cisplatin
Description: tirilizumab administered by intravenous drip (no prophylaxis required) at a fixed dose of 200 mg. each infusion was given for 30 min (not less than 20 min and not more than 60 min) every 3 weeks, and 3 preoperative cycles of albumin-bound paclitaxel 260 mg/m2 and cisplatin 75 mg/m2 on d1, with 1 cycle every 21 days; 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological conditions after surgery; if significant pathological remission (MPR) was achieved, 6 cycles of adjuvant therapy with tirilizumab monotherapy (concurrent radiochemotherapy was available for those with high-risk factors) were performed; if MPR was not achieved, concurrent radiochemotherapy was performed.
Study NCT06470217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: patients underwent direct surgical treatment, with postoperative radiotherapy or radiochemotherapy depending on the presence or absence of histological or pathological high-risk factors.
Study NCT04399616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Map
Description: The tool we test in this project (the visual hazard map) aims to enable the practitioner to quickly identify critical areas for systematically implementing relevant safe practices (appropriate for each situation).
Study NCT04871568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary central dialysis catheterization
Description: Placement of temporary central dialysis catheter
Study NCT04899518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALY688 Ophthalmic Solution
Description: Ophthalmic Solution
Study NCT04899518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALY688 Ophthalmic Solution
Description: Ophthalmic Solution
Study NCT06029153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization
Description: Middle meningeal artery embolization with coil.
Study NCT05008432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Home sleep apnea testing
Description: Participants will be monitored with a WatchPAT device for home based diagnosis of OSA (for patients hospitalized with HFpEF, the sleep test may be performed in the hospital or at home).
Study NCT03637062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
Study NCT06236503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real Stimulation
Description: Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). · Time B:~Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Rest Period: 2 months.
Study NCT06236503 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Stimulation
Description: Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma recovery Scale-R (CRS-R). Time D. Behavioral assessment using the Coma Recovery Scale-R (CRS-R).
Study NCT03637062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pessary
Description: pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
Study NCT05944497 — intervention group
Intervention type: PROCEDURE
Intervention: Interscalene brachial plexus block
Description: Using a linear ultrasound transducer connected to an ultrasound machine, the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery. The transducer is moved cephalad to visualize the 5th to 8th cervical (C5 to C8) nerve roots located between the anterior and middle scalene muscles. Using an in-plane technique, a block needle is inserted close to a nerve root in a lateral-to-medial direction. The needle is moved to place 0.75% ropivacaine around each nerve root. The C8 nerve root is blocked first, and the C5 nerve root is blocked last. After blocking the four cervical nerve roots, ropivacaine is placed in the intermuscular plane between the sternocleidomastoid and scalene muscles to block the supraclavicular nerves. A total of 26 ml of 0.75% ropivacaine is used for the interscalene brachial plexus block (6 ml per nerve root and 2 ml for the supraclavicular nerves).
Study NCT05661929 — intervention group
Intervention type: OTHER
Intervention: Questionnaire CMQ
Description: The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.
Study NCT04551482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 24 IU nasal spray, 4 times per day for 12 weeks
Study NCT04551482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 IU nasal spray, 4 times per day for 12 weeks
Study NCT05855980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound closure
Description: Wound is closed or left open to heal secondarily after amputation.
Study NCT06017895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxepin solution
Description: 2.0 mL doxepin solution (5mg/mL) sprayed to the posterior pharyngeal wall
Study NCT06017895 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.0 mL placebo sprayed to the posterior pharyngeal wall
Study NCT05301283 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Participants will be treated with intensity modulated radiation therapy (IMRT) with photons, which is FDA (U.S. Food and Drug Administration) approved radiation delivery system.
Study NCT05301283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will receive pretreatment diagnostic MRIs to generate MRI habitats. These images will identify radioresistant cells within tumor.
Study NCT05652517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vein of Marshall ethanol infusion
Description: Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
Study NCT05652517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein of Marshall ethanol infusion
Description: Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
Study NCT06353269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estring Vaginal Product
Description: estradiol vaginal ring, exchanged every 12 weeks
Study NCT06353269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vagifem
Description: vaginal estrogen tablet, used twice per week
Study NCT06353269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrace 0.01% Vaginal Cream
Description: vaginal estrogen cream, used twice per week
Study NCT06719791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 0.5 mg per dose for BSA \<1.2 m², 1 mg per dose for BSA 1.3-2.1 m², and 1.5 mg per dose for BSA >2.2 m².
Study NCT06726850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.
Study NCT06726850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS1-144
Description: In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
Study NCT06750640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Infrared thermography
Description: A thermograph (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) was used to record thermal images. The infrared camera was fixed on a tripod 1 m away from the subject to ensure that no shaking movements or vibrations occurred during the recording of thermal images. MDD related acupoints on the inner and outer sides of the limbs were detected. Appropriate body position was selected according to the different parts to be detected. Using the automatic interval saving shooting mode, one thermal picture was taken at 10-s intervals, 3 pictures were taken for each subject.
Study NCT06753825 — intervention group
Intervention type: DEVICE
Intervention: Radiofrequency
Description: radiofrequency treatment
Study NCT06753825 — intervention group
Intervention type: DRUG
Intervention: flunarizine
Description: flunarizine oral treatment
Study NCT06755983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endorphin massage
Description: For Group 1 (experimental group), patients admitted to the clinic one day before surgery will complete the first two sections of the Patient Diagnosis Form (I. Individual characteristics and II. Health and illness-related data), the Surgical Fear and Anxiety Scale, and the VAS scales after the endorphin massage. The patients will be informed that the endorphin massage will last approximately 20 minutes. According to evidence-based current guidelines, it is stated that the intensity of the patient's pain should be assessed during the preoperative period for pain management planning and goals in the postoperative period. Therefore, patients' pain scores will also be recorded preoperatively using the VAS scale. On the morning of the surgery, before going to the operating room, the endorphin massage will be repeated, and the scales will be applied again. After surgery, patients will have their pain levels measured using the VAS at hours 0, 4, 8, 16, and 24, and the amount of analgesics tak
Study NCT06756308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib 100 mg daily on 28-day cycles.
Study NCT06756308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter
Study NCT06752824 — intervention group
Intervention type: DEVICE
Intervention: ANALGESIA NOCICEPTION INDEX MONITORING
Description: INTRACRANIAL SURGERY
Study NCT06752785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T Therapy
Description: CD19/CD22 CAR-T cell therapy
Study NCT06753773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repeated Low-Level Red-Light
Description: All participants will receive a video guide of the Repeated Low-Level Red-Light device. Eligible subjects will receive daily treatment for 14 days, with each treatment lasting for 3 minutes twice a day, with a minimal interval of 4 hours.